InMed Pharmaceuticals Inc.
INM · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $5 | $5 | $4 | $1 |
| % Growth | 7.5% | 11.2% | 279.6% | – |
| Cost of Goods Sold | $3 | $3 | $3 | $1 |
| Gross Profit | $2 | $1 | $1 | $1 |
| % Margin | 34.5% | 23.9% | 33.9% | 49.9% |
| R&D Expenses | $3 | $3 | $4 | $7 |
| G&A Expenses | $7 | $6 | $6 | $7 |
| SG&A Expenses | $7 | $6 | $6 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10 | $9 | $10 | $14 |
| Operating Income | -$8 | -$8 | -$8 | -$14 |
| % Margin | -160.2% | -176.9% | -202.6% | -1,266% |
| Other Income/Exp. Net | -$0 | $0 | $0 | -$5 |
| Pre-Tax Income | -$8 | -$8 | -$8 | -$19 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | -$8 | -$8 | -$19 |
| % Margin | -165.1% | -166.9% | -192.2% | -1,707.3% |
| EPS | -11.44 | -27.55 | -86 | -21,350.51 |
| % Growth | 58.5% | 68% | 99.6% | – |
| EPS Diluted | -11.44 | -27.55 | -86 | -21,350.51 |
| Weighted Avg Shares Out | 1 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 1 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$7 | -$7 | -$8 | -$13 |
| % Margin | -146.8% | -153.6% | -188.2% | -1,219% |